Pulmonary EmbolismNCT06600542
Inari VISION Registry
An observational study of Pulmonary Embolism, run by Inari Medical at 10 sites in 3 countries.
Trial summary
This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Embolism
- What is being tested?
- Inari Medical Commercially Available Devices
- Type of treatment
- Medical device
- How many people
- 1,000 participants
- Where
- 10 sitesin 3 countries
- Study dates
- 7 Mar 2025to 31 Dec 2029
- How long will I take part?
- 180 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have been treated with an Inari Medical device.
Who may be able to join
- Willing and able to provide informed consent per institution and geographical requirements
- Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure.
- Currently within enrollment window relative to their procedure
- Age ≥ 18 years
Who cannot join
- Is or will be inaccessible for registry follow-up
- Meets exclusion criteria required by local requirements
- Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry
- Is pregnant or breastfeeding at the time of enrollment
Trial locations and contacts
10 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
10 sites in 3 countries
United Kingdom8 sites, 8 recruiting
- Recruiting
Southmead Hospital Bristol
Bristol
Peter Mezes, MD
- Recruiting
Queen Elizabeth University Hospital
Glasgow
Peter Douglas, MBChB
- Recruiting
Northwick Park Hospital
London
Jaymin Shah, MD
- Recruiting
Royal Free Hospital
London
Tushar Kotecha, PhD
- Recruiting
Royal London
London
Rashid Akhtar, MBBS
- Recruiting
UCLH University College London Hospital
London
Conrad von Stempel, MBBS
- Recruiting
Royal Victoria Infirmary
Newcastle
John Reicher, BM BCh
- Recruiting
Great Western Hospital
Swindon
Steve Ramcharitar, MD
Italy1 site, 1 recruiting
- Recruiting
Azienda Ospedaliero Universitaria delle Marche
Ancona
Tommaso Piva, MD
Portugal1 site, 1 recruiting
- Recruiting
Santa Marta Hospital
Lisbon
Luís Almeida Morais, MD
About this study
This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.
- Conditions
- Pulmonary Embolism
- Being tested
- Inari Medical Commercially Available Devices
- Medical subject headings
- Pulmonary Embolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inari Medical Commercially Available DevicesDevice
Commercially approved Inari Medical devices
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of device-related, procedure-related, or fatal Adverse Events
Measured: Up to 180 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start7 Mar 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary EmbolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 180 Days
Sponsor and investigators
- Lead sponsor
- Inari Medical
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06600542
- Sponsor's protocol ID
- 24-003
- Status last verified
- Aug 2026
- First submitted
- 15 Aug 2024
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inari VISION Registry
- ClinicalTrials.gov ID
- NCT06600542
- Acronym / sponsor ID
- 24-003
- Conditions
- Pulmonary Embolism
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Inari MedicalIndustry (pharma, biotech, devices)
- Study start
- 7 Mar 2025 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 180 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have been treated with an Inari Medical device.
Key inclusion criteria (4 listed)
- Willing and able to provide informed consent per institution and geographical requirements
- Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure.
- Currently within enrollment window relative to their procedure
- Age ≥ 18 years
Key exclusion criteria (4 listed)
- Is or will be inaccessible for registry follow-up
- Meets exclusion criteria required by local requirements
- Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry
- Is pregnant or breastfeeding at the time of enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inari Medical Commercially Available DevicesCommercially approved Inari Medical devices | Device | – |
Primary outcome
Incidence of device-related, procedure-related, or fatal Adverse Events
Time frame: Up to 180 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
Related trials for Pulmonary Embolism
RecruitingObservational study
Clinical Management and Outcomes After Lung Scintigraphy for Suspected Pulmonary Embolism in the Emergency Department
Pulmonary Embolism (Diagnosis)
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
Not yet recruitingPhase 4
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
Pulmonary Embolism Acute
Active, not recruitingPhase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Pulmonary Embolism
RecruitingObservational study
A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
Acute Pulmonary Embolism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
10 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Embolism, run by Inari Medical at 10 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United Kingdom, Italy, Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ida Nelson (46 707 723010, ida.nelson@inarimedical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of device-related, procedure-related, or fatal Adverse Events (time frame: Up to 180 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.